Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Sorrento Therapeutics, Inc. SRNE
$0.31
На 18:00, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
168363520.00000000
-
week52high
3.09
-
week52low
0.16
-
Revenue
62839000
-
P/E TTM
-1
-
Beta
0.00000000
-
EPS
-1.30000000
-
Last Dividend
0.00000000
-
Next Earnings Date
11 мая 2020 г. в 10:59
Описание компании
Sorrento Therapeutics, Inc., a clinical stage and commercial biopharmaceutical company, develops therapies for cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugate, as well as bispecific antibody approach; and Sofusa, a drug delivery technology that deliver biologic directly into the lymphatic system. Its clinical programs in development include anti-CD38 CAR-T therapy for the treatment of multiple myeloma, as well as for amyloidosis and graft versus host disease. The company develops resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for late stage cancer and osteoarthritis knee pain treatment; and ZTlido, a lidocaine delivery system for the treatment of postherpetic neuralgia. It engages in the development of SEMDEXA, an injectable viscous gel formulation, which is Phase III trial for the treatment of sciatica, a pathology of low back pain; SP-103, an investigational non-aqueous lidocaine topical system undergoing clinical development in chronic low back pain condition; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation for the treatment of fibromyalgia. It has collaboration with SmartPharm Therapeutics Inc. to develop gene-encoded antibody vaccine to protect against COVID-19; Celularity, Inc. for initiating Phase I/II clinical study, including up to 94 patients with COVID-19; Mount Sinai Health System to develop COVI-SHIELD, an antibody therapy targeting SARS-CoV-2 infection; and Mayo Clinic for Phase Ib pilot study using sofusa lymphatic drug delivery technology to deliver Ipilimumab in patient with melanoma. The company was founded in 2006 and is based in San Diego, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| HC Wainwright & Co. | Buy | Buy | 25 мар 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 09 авг 2021 г. |
| Alliance Global Partners | Buy | 21 янв 2021 г. | |
| HC Wainwright & Co. | Buy | Buy | 31 июл 2020 г. |
| Dawson James | Buy | 26 мая 2020 г. | |
| Cantor Fitzgerald | Overweight | 02 ноя 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Покожие компании
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Ji Henry | D | 195 | 3 | 21 дек 2022 г. |
| Ji Henry | A | 500 | 300 | 21 дек 2022 г. |
| Ji Henry | A | 6265805 | 1500000 | 15 дек 2022 г. |
| Ji Henry | D | 198 | 2 | 02 дек 2022 г. |
| Ji Henry | A | 200 | 200 | 02 дек 2022 г. |
| Ji Henry | A | 129 | 129 | 07 сент 2022 г. |
| Ji Henry | A | 759 | 759 | 07 сент 2022 г. |
| Ji Henry | A | 4765805 | 88888 | 07 сент 2022 г. |
| Ji Henry | A | 4676917 | 55555 | 06 сент 2022 г. |
| Ji Henry | A | 4621362 | 2500000 | 02 сент 2022 г. |
Institutional Ownership
Institutional Ownership
| Holder | Shares | Change | Date Reported |
|---|---|---|---|
| SPDR S&P Biotech ETF | 7022300 | -361347 | 31 авг 2020 г. |
| Vanguard Total Stock Market Index Fund | 5068820 | -73438 | 31 авг 2020 г. |
| iShares Russell 2000 ETF | 3750750 | 107464 | 31 авг 2020 г. |
| iShares Russell 2000 Growth ETF | 1626330 | -16024 | 31 авг 2020 г. |
| iShares Micro-Cap ETF | 447698 | 707 | 31 авг 2020 г. |
| Vanguard Extended Market Index Fund | 2309090 | -4748 | 31 июл 2020 г. |
| Invesco DWA Healthcare Momentum ETF | 1913230 | 1913230 | 31 июл 2020 г. |
| Fidelity Extended Market Index Fund | 789990 | -11411 | 31 июл 2020 г. |
| Vanguard Strategic Equity Fund | 671285 | 671285 | 30 июн 2020 г. |
| Fidelity Small Cap Index Fund | 780150 | 124904 | 30 апр 2020 г. |
Новостная лента
A SPAC, Spinoff, And Short Squeeze Walk Into A Bar
Seeking Alpha
24 янв 2023 г. в 15:30
Shares of Scilex could trade higher due to hedging pressure from large Sorrento short positions. Scilex's equity offering facilities, mean that the price could fall precipitously at any time via company dilution.
Sorrento Therapeutics, Scilex: 2 Hot Pharma Stocks On the Move
MarketBeat
13 янв 2023 г. в 12:46
Sorrento Therapeutics is on the move following preliminary results from its subsidiary Scilex. Scilex is making money with the company's 1st product to market
Biggest Penny Stocks Trading Mistakes to Avoid in 2023
PennyStocks
04 янв 2023 г. в 06:00
Avoid making these penny stocks trading mistakes this year The post Biggest Penny Stocks Trading Mistakes to Avoid in 2023 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Sorrento to Host Webcast to Discuss Newly Presented Clinical Data Demonstrating Significant Improvements in Therapeutic Outcomes in 10 of 10 Patients with Poorly Controlled Rheumatoid Arthritis
GlobeNewsWire
13 ноя 2022 г. в 15:02
ATLANTA and SAN DIEGO, Nov. 13, 2022 (GLOBE NEWSWIRE) -- Sofusa®, a wholly-owned division of Sorrento Therapeutics (Nasdaq: SRNE, “Sorrento”), today announced that it will host a virtual Key Opinion Leader (KOL) panel discussion titled “Empowering the Lymphatics: Unleashing the Potential of Biologics that Target the Immune System” to be held on Thursday, November 17, 2022 at 11:30 AM EST.
Sorrento: Limited Potential, High Management Compensation, Complicated Lawsuits
Seeking Alpha
09 ноя 2022 г. в 14:29
Sorrento Therapeutics has been in the limelight for all the wrong reasons. Its R&D is just a byproduct of its business.